

Gonzalez Alejandro  
Form SC 13G/A  
February 05, 2009

OMB APPROVAL  
OMB Number: 3235-0145  
Expires: February 28, 2009  
Estimated average burden  
hours per response...10.4

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. 5)\***

**La Jolla Pharmaceutical Company**

(Name of Issuer)

Common Stock

(Title of Class of Securities)

503459109

(CUSIP Number)

Calendar Year 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 503459109

NAMES OF REPORTING PERSONS

1

Alejandro Gonzalez

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Mexico

SOLE VOTING POWER

5

NUMBER OF 9,343,839

SHARED VOTING POWER

6

SHARES BENEFICIALLY OWNED BY

None

SOLE DISPOSITIVE POWER

7

EACH REPORTING PERSON

9,343,839

SHARED DISPOSITIVE POWER

8

WITH:

None

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

9,343,839

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

16.5%

**12** TYPE OF REPORTING PERSON

IN

**Item 1.**

|   |   |
|---|---|
| (a) Name of Issuer                                  | La Jolla Pharmaceutical Company               |
| (b) Address of Issuer's Principal Executive Offices | 6455 Nancy Ridge Drive<br>San Diego, CA 92121 |

**Item 2.**

|  |  |
|--|--|
| (a) Name of Person Filing  | Alejandro Gonzalez   |
| (b) Address of Principal Business Offices or, if none, Residence | Ruben Dario #223 5-A<br>Chapultepec Morales<br>Mexico D.F. 11570 |
| (c) Citizenship  | Mexico   |
| (d) Title of Class of Securities                                 | Common Stock   |
| (e) CUSIP Number   | 503459109  |

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

\_\_\_\_\_

Page 3 of 5 pages

---

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount Beneficially Owned: 9,343,839<sup>1</sup>.
- (b) Percent of Class: 16.5%<sup>2</sup>.
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 9,343,839.
  - (ii) Shared power to vote or to direct the vote: None.
  - (iii) Sole power to dispose or to direct the disposition of: 9,343,839.
  - (iv) Shared power to dispose or to direct the disposition of: None.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. o

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

<sup>1</sup> Includes 8,205,692 outstanding shares and an additional 1,138,147 shares underlying outstanding warrants.

<sup>2</sup> Based upon 55,421,634 shares

outstanding as  
of November 3,  
2008. Also  
gives effect to  
exercise of the  
warrants  
referenced in  
Note 1 above.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that that information set forth in this statement is true, complete and correct.

February 5, 2008

Date

/s/ Alejandro Gonzalez

Signature

Alejandro Gonzalez

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power or attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)**